Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Vectus Biosystems (ASX:VBS) exits VB4-P5—can this microcap regain momentum with VB0004?
Vectus Biosystems signs US$3M deal to license VB4-P5 to XORTX. Can its lead fibrosis drug VB0004 now deliver the next big upside?
Amgen and AstraZeneca win FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Find out how Amgen and AstraZeneca’s Tezspire approval for nasal polyps redefines biologic therapy and reshapes investor confidence today.
MapLight Therapeutics sets sights on Nasdaq IPO as CNS pipeline advances toward pivotal trials
MapLight Therapeutics files for Nasdaq IPO to raise $250M for schizophrenia and Alzheimer’s trials. Find out what’s next for this neuroscience innovator.
Kiniksa’s KPL-387 earns FDA orphan drug nod, advancing next-gen therapy for recurrent pericarditis
Find out how Kiniksa’s KPL-387 won FDA orphan drug status for pericarditis — and what it means for the company’s expanding rare-disease franchise.
TROPION-PanTumor03 trial reports breakthrough responses with DATROWAY and Rilvegostomig combo in bladder cancer
Discover how DATROWAY plus rilvegostomig is rivaling the EV-302 standard with high response rates in metastatic urothelial cancer.
Eledon prepares to reveal critical Phase 2 tegoprubart findings at ASN Kidney Week 2025 — a potential transplant game-changer
Find out how Eledon’s tegoprubart Phase 2 BESTOW trial debut at ASN 2025 could reshape kidney transplant immunosuppression strategies — read more.
Summit Therapeutics launches global Phase III HARMONi-GI3 trial as ivonescimab enters colorectal cancer race
Find out how Summit Therapeutics and Akeso are betting on ivonescimab’s expansion into colorectal cancer and why investors see it as a defining moment for the biotech’s future.
XORTX surges after $3M Vectus Biosystems deal adds promising anti-fibrotic kidney drug to pipeline
Find out how XORTX’s $3 million Vectus Biosystems acquisition could reshape the renal fibrosis market and accelerate its transformation into a leading kidney disease innovator.
AbbVie completes $1.2bn acquisition of Gilgamesh’s bretisilocin: Is big pharma finally embracing psychedelic psychiatry?
AbbVie completes $1.2B acquisition of bretisilocin from Gilgamesh, betting big on short-acting psychiatric drugs. Here’s what the deal signals for depression care.
Rani Therapeutics seals $1.085bn Chugai deal and $60m oversubscribed financing to fuel oral biologics push
Rani Therapeutics secured a $1.085 B Chugai collaboration and an oversubscribed $60.3 M raise. Find out how this dual deal could redefine its biotech trajectory.